July - 202019TECH OUTLOOKTransforming Pharma Portfolio Analytics to Maximize Business ImpactBy Wenjia You, Director, Head of Global Portfolio Management - Valuation & Analytics, EMD Serono [EPA:SAN]Portfolio analytics core to pharma portfolio decision makingThe pharma industry has experienced productivity decline for decades, measured by many metrics including return on R&D investment and the number of New Molecular Entity approved per billion dollars spent. Maximizing value creation from pharma R&D investment, therefore, has been a focal point for the industry, and recent data explosion as well as advancement in analytical tools holds excellent promise in leveraging pharma analytics to maximize business impact.A lot is at stake when it comes to pharma portfolio decision making, whether on funding a project to the next phase, taking on a program with multiple indications, seeking to partner for financial or capabilities reasons, or filling a portfolio gap through acquisition or in-licensing. Decisions are often tied with significant investment up to billions of dollars and have both immediate and far-reaching impact within the organization. In the broader context of declining pharma productivity, it is ever more critical to make informed portfolio decisions anchored in facts and analytics to more effectively allocate financial and people resources.Portfolio analytics is at the heart of pharma analytics, by aggregating the most critical data points across the organization for pharma assets (pipeline projects and inline products), from research to development, commercial, Manufacturing, and other supporting functions (e.g., Forecasting, Competitive Intelligence), to inform on portfolio decision making and maximize value of pharma investment.Central to portfolio analytics is the "value triangle," composed of opportunities, risks, and uncertainties for projects, programs, and portfolios. Key inputs across projects (including the probability Wenjia YouCXO INSIGHTS
< Page 9 | Page 11 >